Purpose & Methods: Neuroendocrine neoplasms are a heterogenous group of tumours, for which nuclear medicine plays an important role in the diagnostic work-up as well as in the targeted therapeutic options. This guideline is aimed to assist nuclear medicine physicians in recommending, performing, reporting and interpreting the results of somatostatin receptor (SSTR) PET/CT imaging using 68Ga-DOTA-conjugated peptides, as well as 18F-DOPA imaging for various neuroendocrine neoplasms. Results & Conclusion: The previous procedural guideline by EANM regarding the use PET/CT tumour imaging with 68Ga-conjugated peptides has been revised and updated with the relevant and recent literature in the field with contribution of distinguished experts.
Mendeley helps you to discover research relevant for your work.
CITATION STYLE
Bozkurt, M. F., Virgolini, I., Balogova, S., Beheshti, M., Rubello, D., Decristoforo, C., … Fanti, S. (2017). Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F–DOPA. European Journal of Nuclear Medicine and Molecular Imaging, 44(9), 1588–1601. https://doi.org/10.1007/s00259-017-3728-y